Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
This review analyses existing literature, including authors' own data, describing the results of clinical trials which assess safety and efficacy of insulin Glargine (Lantus?) in children and adolescents, as well as peculiar features of T1D management in this age group, including the challenge...
Guardado en:
Autor principal: | Tamara Leonidovna Kuraeva |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/947bfb4adf1b459f8c9e536232bf74b8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Basal insulin therapy in patients with type 2 diabetes mellitus and poor control of glycemia by oral hypoglycemic agents: results of direct comparative study of insulin analogs Lantus and Levemir
por: Alsu Gafurovna Zalevskaya, et al.
Publicado: (2010) -
Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
Insulin degludec is a new ultra-long-acting insulin analogue
por: Ivan Ivanovich Dedov, et al.
Publicado: (2014) -
The role of insulin analogs in the achievement of compensation and improvement of quality of life in children and adolescents with type 1 diabetes mellitus
por: Tamara Leonidovna Kuraeva
Publicado: (2010)